Bioptigen has pioneered a new class of in vivo optical imaging systems for biomedical applications. These systems enable real-time non-invasive imaging of internal tissue microstructure, advancing critical applications in drug development, genetics research, tissue engineering, and medical vision.
Bioptigen is a spin-out of the Duke University Biomedical Engineering Department. Bioptigen was incorporated in North Carolina in August, 2004, to commercialize technologies originating in the laboratories of Professor Joseph Izatt. Bioptigen technology is based on the science of Optical
Coherence Tomography (OCT), an imaging system similar in function to ultrasound, but using low-power light rather than sound waves. OCT offers resolution 100-times finer than standard ultrasound, suitable for analyzing tissue microstructure with features smaller than 10 micrometer.
Bioptigen has pioneered a new generation of OCT technology with imaging speed 50 to 100 times faster than the competition. This dramatic speed increase leads to superior image quality, creates a new user experience with immediate feedback, extends the application space to diagnostics of uncooperative subjects, and enables a new class of image-guided interventions. Bioptigen advances further enable new functional imaging capabilities, including Doppler quantification of blood flows in living tissues. URL: http://www.bioptigen.com/